SCHEMBL3295244

SCHEMBL3295244

CCCCCC=CB(O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.44
TRPV1 Q8NER1 1/20 0.44
TERT O14746 3/20 0.43
PTPN1 P18031 3/20 0.43
PPARG P37231 3/20 0.43
PPARD Q03181 3/20 0.43
PPARA Q07869 3/20 0.43
CYP1A2 P05177 2/20 0.43
MAPT P10636 2/20 0.43
CYP2C19 P33261 2/20 0.43
BLM P54132 2/20 0.43
HSD17B10 Q99714 2/20 0.43
FABP4 P15090 2/20 0.43
KMT2A Q03164 2/20 0.43
TOP1 P11387 2/20 0.43
GMNN O75496 1/20 0.43
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2619762 1.00 FAAH (0.44) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL1334737 0.98 FAAH (0.48) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL2619763 0.98 FAAH (0.48) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL4187797 0.98 FAAH (0.48) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL542661 0.98 FAAH (0.48) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL542662 0.98 FAAH (0.48) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL1334740 0.98 FAAH (0.48) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL13320972 0.98 FAAH (0.48) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL157037 0.92
SCHEMBL29955736 0.92

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112608260-B Method for synthesizing aromatic vinyl trifluoro-methyl sulfide compound by removing boric acid 江南大学 2022-06-10 CN claimed
CN-112608260-A Method for synthesizing aromatic vinyl trifluoro-methyl sulfide compound by removing boric acid 江南大学 2021-04-06 CN claimed
US-20220119569-A1 Curable and Solvent Soluble Formulations and Methods of Making and Using Therof POLY6 TECHNOLOGIES, INC. 2022-04-21 US disclosed
US-20200062877-A1 Curable and Solvent Soluble Formulations and Methods of Making and Using Therof POLY6 TECHNOLOGIES, INC. 2020-02-27 US disclosed
WO-2018156766-A2 CURABLE AND SOLVENT SOLUBLE FORMULATIONS AND METHODS OF MAKING AND USING THEREOF POLY6 TECHNOLOGIES, INC. (US) 2018-08-30 WO disclosed
US-20150315127-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2015-11-05 US disclosed
US-8404731-B2 Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors TRANSTECH PHARMA, INC. (US) 2013-03-26 US disclosed
US-20120196906-A1 Substituted Imidazole Derivatives, Compositions, and Methods of Use as PTPase Inhibitors TRANSTECH PHARMA, INC. (US) 2012-08-02 US disclosed
US-7820670-B2 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions ALCON RESEARCH, LTD. (US) 2010-10-26 US disclosed
EP-2209764-A1 GSM INTERMEDIATES Janssen Pharmaceutica, N.V. (BE) 2010-07-28 EP disclosed
US-7723369-B2 Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors TRANSTECH PHARMA, INC. (US) 2010-05-25 US disclosed
WO-2009052341-A1 GSM INTERMEDIATES JANSSEN PHARMACEUTICA, N.V. (BE) 2009-04-23 WO disclosed
EP-1991544-A2 SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS Transtech Pharma, Inc. (US) 2008-11-19 EP disclosed
US-20080177095-A1 FUROCHROMAN DERIVATIVES MERCK PATENT GMBH (DE) 2008-07-24 US disclosed
US-20080153813-A1 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS ALCON MANUFACTURING, LTD. (US) 2008-06-26 US disclosed
US-20070191385-A1 Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors VTV THERAPEUTICS LLC 2007-08-16 US disclosed
WO-2007089857-A2 SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS TRANSTECH PHARMA, INC. (US) 2007-08-09 WO disclosed
US-6593480-B2 Obesity, hyperglycemia ABBOTT LABORATORIES 2003-07-15 US disclosed
WO-2002070507-A2 GLYCORTICOID RECEPTOR ANTAGONISTS FOR TREATMENT OF DIABETES ABBOTT LABORATORIES (US) 2002-09-12 WO disclosed
US-20010041802-A1 Glucocorticoid receptor antagonists for treatment of diabetes KARO BIO AB (SE) 2001-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080177095-A1 FUROCHROMAN DERIVATIVES CFD, LMAN1, UROD FAAH 4105/4885TRPV1 584/4885TERT 2687/4885
US-20010041802-A1 Glucocorticoid receptor antagonists for treatment of diabetes NR3C1, GPR119, NR3C2 FAAH 1754/4885TRPV1 2348/4885TERT 4217/4885
US-20150315127-A1 THERAPEUTIC COMPOUNDS HTR2C, GRK2, GRK3 FAAH 1491/4885TRPV1 255/4885TERT 4852/4885
US-20070191385-A1 Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors PTP4A1, PTPRJ, PTP4A2 FAAH 3723/4885TRPV1 2102/4885TERT 2464/4885
US-20120196906-A1 Substituted Imidazole Derivatives, Compositions, and Methods of Use as PTPase Inhibitors PTP4A1, PTPRJ, PTP4A2 FAAH 3723/4885TRPV1 2102/4885TERT 2464/4885
US-20080153813-A1 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS ROCK2, ROCK1, RHOT2 FAAH 3192/4885TRPV1 3576/4885TERT 1793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.